CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
7.54
-0.60 (-7.37%)
At close: Aug 14, 2026, 4:00 PM EDT
7.59
+0.05 (0.68%)
After-hours: Aug 14, 2026, 5:55 PM EDT
CorMedix Revenue
CorMedix had revenue of $101.93M in the quarter ending June 30, 2026, with 156.52% growth. This brings the company's revenue in the last twelve months to $462.25M, up 280.50% year-over-year. In the year 2025, CorMedix had annual revenue of $311.71M with 617.03% growth.
Revenue (ttm)
$462.25M
Revenue Growth
+280.50%
P/S Ratio
1.27
Revenue / Employee
$2,420,152
Employees
191
Market Cap
587.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 311.71M | 268.24M | 617.03% |
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
| Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
| Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
| Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
| Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
| Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
| Dec 31, 2013 | 2.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 355.17M |
| Arvinas | 316.70M |
| ARS Pharmaceuticals | 116.93M |
| 4D Molecular Therapeutics | 92.01M |
| Verastem | 87.53M |
| Assembly Biosciences | 74.85M |
| Prelude Therapeutics | 22.42M |
| Altimmune | 31.00K |
CRMD News
- 1 day ago - CorMedix Earnings Call Transcript: Q2 2026 - Transcripts
- 1 day ago - CorMedix Earnings release: Q2 2026 - Filings
- 1 day ago - CorMedix Quarterly report: Q2 2026 - Filings
- 1 day ago - Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 - GlobeNewsWire
- 5 weeks ago - CorMedix price target lowered to $13 from $14 at RBC Capital - TheFly
- 7 weeks ago - CorMedix Transcript: AGM 2026 - Transcripts
- 2 months ago - CorMedix announces United States Court of Appeals affirms patent judgements - TheFly